Market strategist Sudip Bandyopadhyay outlines a nuanced sector roadmap for investors. State Bank of India's post-results selloff presents a buying opportunity, with strong credit growth of 16%, healthy net interest margins, and controlled NPAs offsetting modest NPA slippage concerns. The stock trades at just 10-11 times earnings. Indian pharma stands on the cusp of a multi-decade rally, with Sun Pharma's Organon acquisition transforming its branded product portfolio to 70%. Aurobindo Pharma and Mankind Pharma offer attractive valuations. Consumption stocks warrant caution over the next two quarters due to El Niño-linked monsoon risks, though large-cap FMCG leaders like HUL and Nestle remain defensive choices. Capital goods emerge as the highest conviction play, with quality names like L&T, BHEL, Thermax, and GE Vernova offering compelling long-term entry points on any price weakness.
Post from MarketNews_en
Log in to interact with content.